Last reviewed · How we verify
Oseltamivir(oral)
Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread.
Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread. Used for Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age, Prophylaxis of influenza A and B in patients ≥1 year of age.
At a glance
| Generic name | Oseltamivir(oral) |
|---|---|
| Sponsor | Guangdong Raynovent Biotech Co., Ltd |
| Drug class | Neuraminidase inhibitor |
| Target | Influenza neuraminidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Oseltamivir is a prodrug that is converted to its active form (oseltamivir carboxylate) in the body. The active metabolite inhibits influenza neuraminidase, an enzyme on the viral surface required for the virus to escape from infected host cells. By blocking neuraminidase, the drug prevents viral release and transmission to uninfected cells, thereby reducing the duration and severity of influenza infection.
Approved indications
- Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age
- Prophylaxis of influenza A and B in patients ≥1 year of age
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Headache
- Diarrhea
Key clinical trials
- Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza (PHASE2)
- Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza (PHASE3)
- Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A (PHASE3)
- Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza (PHASE3)
- Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza (PHASE3)
- A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension (PHASE3)
- Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oseltamivir(oral) CI brief — competitive landscape report
- Oseltamivir(oral) updates RSS · CI watch RSS
- Guangdong Raynovent Biotech Co., Ltd portfolio CI